Stem Cell Therapies in Regenerative Medicine and Diabetes Mellitus: Advances, Constraints and Future Prospects
Journal Title: Journal of Transplantation & Stem Cell Biology - Year 2016, Vol 3, Issue 1
Abstract
Stem cell therapy is one of the most promising treatments for the near future. This kind of therapy can ameliorate or even reverse some diseases and have potential applications in regenerative and replacement medicines and diabetes mellitus. The different types of stem cells such as embryonic stem cells, induced pluripotent stem cells and adult stem cells have been proved to be operational in treating diabetes mellitus with clear limitations. The prevalence of diabetes mellitus type 1 and type 2 continues to rise and its complications are serious and may lead to death. The current treatment methods, other than stem cell therapy, do not treat the main causes of the disease and have many limitations. Although insulin injection is the standard therapy for type 1 diabetes mellitus, its exogenous injection cannot mimic insulin secretion from normal β-cells when blood glucose changes all the time. Thus, how to generate new β-cells is an important approach for the treatment of type 1 diabetes mellitus. Isolated islets are fragile and susceptible to pro-apoptotic factors and poorly proliferative. In contrast, mesenchymal stem cells (MSCs) are highly proliferative, anti-apoptotic and pluripotent to differentiate toward various cell types. The electrofusion between islets´ cells and MSCs produced fusion islets´ cells that are more resistant to apoptosis and are able to maintain insulin secretion for long periods. The stem cell therapy is also used for treatment of type 2 diabetes mellitus as well because the disease later progresses to β-cell dysfunction. Stem cell therapies were clinically applied for improvement of insulin sensitivity and metabolic control in long standing type 2 diabetes mellitus. In addition to the applications of stem cells in the cell therapy of diabetes mellitus, recent trends of studies tend to use the direct reprogrammed adult somatic cells especially endoderm-derived adult cells transdifferentiated into insulin secretory pancreatic β-cells. However, the use of stem cells especially human embryonic stem cells in research and therapy is subjected to limitations and constraints in many countries due to ethical and religious concerns. In this article, the types of stem cells and their resources and to what extent stem cell research can lead to progresses in regenerative medicine and diabetes mellitus therapies are reviewed. It also sheds light on ethical concerns and future hopes of stem cell use in research and therapy.
Authors and Affiliations
Ahmed OM
Generation of Neural Cells by Direct Cellular Reprogramming
Cellular reprogramming is a new technique that is currently explored for its potential to manufacture human cell types in vitro. Direct cellular reprogramming allows the direct conversion of cells into a target cell type...
Organ Bioengineering, Regeneration and Repair: Where the Future of Organ Transplantation is Taking Shape
Although organ transplantation is now widely viewed as one of the monumental achievements in the history of modern medicine, that was not always the case. Indeed, back at the beginning of the 20th century the idea of rep...
Stem Cell Therapies in Regenerative Medicine and Diabetes Mellitus: Advances, Constraints and Future Prospects
Stem cell therapy is one of the most promising treatments for the near future. This kind of therapy can ameliorate or even reverse some diseases and have potential applications in regenerative and replacement medicines a...
Scaffold Free 3D Culture of Mesenchymal Stem Cells; Implications for Regenerative Medicine
Mesenchymal stem cells (MSCs) are recognized as important sources for regenerative medicine (RM). Adherent cultures, long time considered definitory for MSCs phenotype, are relatively easy to perform and to assess. Two d...
Therapeutic Effect of Genistein-Stimulated Human Mesenchymal Stem Cells in Myocardial Infarction
Stem cells offer significant therapeutic promise for the treatment of ischemic diseases. However, stem cells transplanted into ischemic tissue exhibit limited therapeutic efficacy because of poor engraftment in vivo. Sev...